title: Presentation of smoking-associated cues does not elicit dopamine release after one-hour smoking abstinence: A [11C]-(+)-PHNO PET study.
abstract: The presentation of drug-associated cues has been shown to elicit craving and dopamine release in the striatum of drug-dependent individuals. Similarly, exposure to tobacco-associated cues induces craving and increases the propensity to relapse in tobacco- dependent smokers. However, whether exposure to tobacco-associated cues elicits dopamine release in the striatum of smokers remains to be investigated. We hypothesized that presentation of smoking-related cues compared to neutral cues would induce craving and elevation of intrasynaptic dopamine levels in subregions of the striatum and that the magnitude of dopamine release would be correlated with subjective levels of craving in briefly abstinent tobacco smokers. Eighteen participants underwent two [(11)C]-(+)-PHNO positron emission tomography (PET) scans after one-hour abstinence period: one during presentation of smoking-associated images and one during presentation of neutral images. Smoking cues significantly increased craving compared to neutral cues on one, but not all, craving measures; however, this increase in craving was not associated with overall significant differences in [(11)C]-(+)-PHNO binding potential (BPND) (an indirect measure of dopamine release) between the two experimental conditions in any of the brain regions of interest sampled. Our findings suggest that presentation of smoking cues does not elicit detectable (by PET) overall increases in dopamine in humans after one-hour nicotine abstinence. Future research should consider studying smoking cue-induced dopamine release at a longer abstinence period, since recent findings suggest the ability of smoking-related cues to induce craving is associated with a longer duration of smoking abstinence.
authors.affiliation: Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, Canada.
authors.forename: Lina
authors.initials: L
authors.lastname: Chiuccariello
authors.forename: Isabelle
authors.initials: I
authors.lastname: Boileau
authors.forename: Mihail
authors.initials: M
authors.lastname: Guranda
authors.forename: Pablo M
authors.initials: PM
authors.lastname: Rusjan
authors.forename: Alan A
authors.initials: AA
authors.lastname: Wilson
authors.forename: Laurie
authors.initials: L
authors.lastname: Zawertailo
authors.forename: Sylvain
authors.initials: S
authors.lastname: Houle
authors.forename: Usoa
authors.initials: U
authors.lastname: Busto
authors.forename: Bernard
authors.initials: B
authors.lastname: Le Foll
mesh_terms: D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D012907:Smoking / Q000378:metabolism*; D016540:Smoking Cessation; D013375:Substance Withdrawal Syndrome / Q000000981:diagnostic imaging / Q000378:metabolism; D055815:Young Adult
chemical_list: D004298:Dopamine
references.citation: J Neurosci. 2000 May 15;20(10):3874-83
references.pmid: 10804227
references.citation: J Neurosci. 2007 Apr 11;27(15):3998-4003
references.pmid: 17428975
references.citation: Psychopharmacology (Berl). 2009 May;204(1):25-35
references.pmid: 19107465
references.citation: Neuropsychopharmacology. 2007 Nov;32(11):2301-9
references.pmid: 17375140
references.citation: J Neurosci. 2009 May 13;29(19):6176-85
references.pmid: 19439595
references.citation: Neuropsychopharmacology. 2005 Oct;30(10):1940-7
references.pmid: 15920499
references.citation: J Neurosci. 2003 Dec 10;23(36):11461-8
references.pmid: 14673011
references.citation: J Cereb Blood Flow Metab. 2000 Mar;20(3):423-51
references.pmid: 10724107
references.citation: Neuropsychopharmacology. 2008 Jan;33(2):279-89
references.pmid: 17406650
references.citation: Nicotine Tob Res. 2003 Oct;5(5):645-54
references.pmid: 14577981
references.citation: Neuroimage. 2011 Jan 1;54(1):264-77
references.pmid: 20600980
references.citation: Am J Psychiatry. 2002 Jun;159(6):954-60
references.pmid: 12042183
references.citation: Addict Behav. 2005 Sep;30(8):1587-91
references.pmid: 15890458
references.citation: J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
references.pmid: 9881538
references.citation: J Neurophysiol. 1998 Jul;80(1):1-27
references.pmid: 9658025
references.citation: Neuropsychopharmacology. 2006 Dec;31(12):2728-38
references.pmid: 16598192
references.citation: Arch Gen Psychiatry. 1986 Mar;43(3):289-94
references.pmid: 3954551
references.citation: J Med Chem. 2005 Jun 16;48(12):4153-60
references.pmid: 15943487
references.citation: Nature. 2003 Apr 10;422(6932):614-8
references.pmid: 12687000
references.citation: Biol Psychiatry. 2010 Apr 15;67(8):722-9
references.pmid: 20172508
references.citation: Neuropsychopharmacology. 2005 May;30(5):853-63
references.pmid: 15549053
references.citation: Psychopharmacology (Berl). 2006 Mar;184(3-4):577-88
references.pmid: 16133128
references.citation: Alcohol Clin Exp Res. 2002 Mar;26(3):318-25
references.pmid: 11923583
references.citation: Br J Addict. 1991 Nov;86(11):1467-76
references.pmid: 1777741
references.citation: J Cereb Blood Flow Metab. 2012 Jan;32(1):127-36
references.pmid: 21878947
references.citation: Curr Opin Neurobiol. 1997 Apr;7(2):191-7
references.pmid: 9142754
references.citation: Psychopharmacology (Berl). 2006 Aug;187(3):385-96
references.pmid: 16752139
references.citation: J Cereb Blood Flow Metab. 2003 Mar;23(3):285-300
references.pmid: 12621304
references.citation: Neuroimage. 2013 Mar;68:119-32
references.pmid: 23207573
references.citation: Addict Behav. 1989;14(4):419-28
references.pmid: 2782124
references.citation: J Consult Clin Psychol. 1992 Oct;60(5):689-97
references.pmid: 1401384
references.citation: Tob Control. 2001 Dec;10(4):396-7
references.pmid: 11806351
references.citation: Psychiatry Res. 2006 Jun 30;147(1):79-89
references.pmid: 16797168
references.citation: J Nucl Med. 2010 Mar;51(3):496-7
references.pmid: 20150251
references.citation: Behav Res Ther. 1988;26(3):225-33
references.pmid: 3408457
references.citation: Br J Addict. 1991 Sep;86(9):1119-27
references.pmid: 1932883
references.citation: Drug Alcohol Rev. 2007 Jan;26(1):25-31
references.pmid: 17364833
references.citation: Eur Neuropsychopharmacol. 2008 Apr;18(4):262-70
references.pmid: 18077142
references.citation: Addict Biol. 2011 Jan;16(1):166-75
references.pmid: 20331560
references.citation: Neuropsychopharmacology. 2008 Aug;33(9):2148-57
references.pmid: 17987060
references.citation: Behav Pharmacol. 1996 Nov;7(7):669-674
references.pmid: 11224464
references.citation: Neuropsychopharmacology. 2006 Dec;31(12):2716-27
references.pmid: 16971900
references.citation: Neuropsychopharmacology. 2006 Mar;31(3):644-50
references.pmid: 16123763
references.citation: Addict Behav. 2010 Feb;35(2):164-7
references.pmid: 19836144
references.citation: Addict Behav. 1998 Mar-Apr;23(2):209-24
references.pmid: 9573425
references.citation: J Consult Clin Psychol. 2000 Apr;68(2):233-40
references.pmid: 10780123
references.citation: Alcohol Clin Exp Res. 1999 Nov;23(11):1751-60
references.pmid: 10591591
references.citation: J Neurosci. 2000 Oct 1;20(19):7489-95
references.pmid: 11007908
references.citation: Addiction. 2002 Jan;97(1):87-93
references.pmid: 11895274
references.citation: J Neurosci. 2006 Jun 14;26(24):6583-8
references.pmid: 16775146
references.citation: Neuroimage. 1996 Dec;4(3 Pt 1):153-8
references.pmid: 9345505
references.citation: Biol Psychiatry. 2011 Apr 1;69(7):708-11
references.pmid: 20817135
references.citation: Exp Clin Psychopharmacol. 2004 Aug;12(3):208-15
references.pmid: 15301638
references.citation: Pharmacol Rev. 2005 Mar;57(1):79-115
references.pmid: 15734728
references.citation: J Neurochem. 2006 May;97(4):1089-103
references.pmid: 16606355
references.citation: Arch Gen Psychiatry. 2002 Dec;59(12):1162-72
references.pmid: 12470133